deltatrials
Terminated PHASE1 INTERVENTIONAL 8-arm NCT04422210

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

A Phase Ib Dose-Escalation and Dose-Expansion Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Patients With Untreated Extensive-Stage Small Cell Lung Cancer.

Sponsor: Hoffmann-La Roche

Conditions Small Cell Lung Cancer
Interventions Atezolizumab Carboplatin Etoposide Venetoclax
Updated 16 times since 2020 Last updated: Oct 8, 2021 Started: Sep 22, 2020 Primary completion: Nov 6, 2020 Completion: Nov 6, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Decision to discontinue the study based on broader development and strategic prioritisation. The Sponsor concludes there is no benefit-risk impact on the GO41864 study.

Other terminated trials from Hoffmann-La Roche

See all terminations from Hoffmann-La Roche

Other Small Cell Lung Cancer trials with similar outcome

Browse all Small Cell Lung Cancer trials

This PHASE1 trial investigates Small Cell Lung Cancer and is currently terminated or withdrawn. Hoffmann-La Roche leads this study, which shows 16 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Apr 2021 · 59 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1

▶ Show 11 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE1

  2. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE1

    Status: Completed → Terminated

  3. Jun 2021 — Sep 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  4. Apr 2021 — Jun 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2021 — Apr 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  7. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  8. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  9. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE1

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE1

  11. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hoffmann-La Roche
Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations